10-K: Viking Therapeutics Releases 10-K Filing, Highlights Clinical Progress and Financial Position

Sentiment:

Annual Report (Form 10-K) 7 February 2024 5:24 PM

📋All filings for Viking Therapeutics, INC

Viking Therapeutics' 10-K filing details the company's clinical advancements, financial standing, and future strategies in developing therapies for metabolic and endocrine disorders.

Capital raiseThe company may need to seek additional equity or debt financing to provide the capital required to maintain or expand its operations.On July 26, 2023, the company filed an automatic universal shelf registration statement on Form S-3 (File No. 333-273460) with the SEC as a well-known seasoned issuer.The 2023 Shelf Registration Statement allows the company to offer an indeterminate amount of securities, including equity securities, debt securities, warrants, rights, units and depositary shares, from time to time as described in the 2023 Shelf Registration Statement.The 2023 Shelf Registration Statement includes a prospectus, or the ATM Prospectus, pursuant to which the company may offer and sell, from time to time, through or to Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc., H.C. Wainwright & Co. LLC and BTIG, LLC, or, collectively, the ATM Agents, as sales agent(s) or principal(s), shares of its common stock having an aggregate offering price of up to $200.0 million, or the ATM Offering.

Summary

Viking Therapeutics, a clinical-stage biopharmaceutical company, filed its 10-K report for the fiscal year ended December 31, 2023.
The company is focused on developing novel therapies for metabolic and endocrine disorders.
Key clinical programs include VK2809 for NASH, VK2735 for metabolic disorders and obesity, and VK0214 for X-ALD.
The VOYAGE study, a Phase 2b clinical trial of VK2809, achieved its primary endpoint, showing statistically significant reductions in liver fat content.
Results from the biopsy after 52 weeks of dosing are expected to be available in 2024.
The Phase 2 VENTURE study of VK2735 in obese patients completed enrollment, with data expected in the first half of 2024.
A Phase 1 clinical study of an oral formulation of VK2735 has been initiated.
VK0214 is in a Phase 1b clinical trial for X-ALD, targeting enrollment across three cohorts.
The company is also pursuing partnering or licensing opportunities for VK5211, a SARM for hip fracture recovery.
As of December 31, 2023, the company had cash, cash equivalents, and investments totaling $362.1 million.
Management believes these funds will be sufficient to fund operations through at least the first quarter of 2025.
The company expects to continue incurring losses and will need to raise additional capital in the future.
The company is subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our drug candidates.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results and a strong cash position are encouraging, but ongoing losses and the need for future capital raises introduce uncertainty.

Positives

The VOYAGE study achieved its primary endpoint, demonstrating statistically significant reductions in liver fat content.
The Phase 2 VENTURE study completed enrollment, with data expected soon.
The company has a strong cash position of $362.1 million, expected to fund operations through at least Q1 2025.
VK2809 has been evaluated in eight completed clinical studies, which enrolled more than 300 subjects, with no serious adverse events observed.

Negatives

The company has incurred losses and negative cash flows from operations since its inception.
The company expects to continue incurring losses and will need to raise additional capital in the future.
The company is subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our drug candidates.

Risks

The company is dependent on the success of its drug candidates, and there is no guarantee of regulatory approval or commercialization.
Delays in clinical trials could increase costs and delay strategic collaborations.
The company relies on third parties for preclinical studies and clinical trials, which poses risks if these parties fail to meet their obligations.
Competitors may develop more effective or less costly therapies.
Unstable market and economic conditions could adversely affect the company's business and financial condition.
The company may not be successful in obtaining or maintaining necessary rights to its drug candidates through acquisitions and in-licenses.
The company may infringe the intellectual property rights of others, which may prevent or delay our drug development efforts and prevent us from commercializing or increase the costs of commercializing our products.

Future Outlook

The company expects to continue incurring losses and will need to raise additional capital to fund its operations and complete ongoing and planned clinical trials.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Viking faces competition from numerous companies developing therapies for NASH, obesity, X-ALD, and other metabolic disorders.

Comparison to Industry Standards

VK2735, if approved, will compete against therapies that are already approved and marketed for obesity, including Semaglutide (Wegovy) and liraglutide (Saxenda) from Novo Nordisk A/S, and tirzepatide (Zepbound) from Eli Lilly and Company.
VK0214, if approved, will face competition from experimental therapies that are in various stages of clinical development for X-ALD by companies, including Minoryx Therapeutics S.L., Neuraxpharm Group, Poxel SA, and SwanBio Therapeutics, Inc.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Clawback Policy	The Board of Directors adopted a Clawback Policy, which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement.	2023-10-02	The Clawback Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Securities Exchange Act of 1934, as amended (the Exchange Act), Rule 10D-1 promulgated under the Exchange Act (Rule 10D-1) and Nasdaq Listing Rule 5608 (the Listing Standards).

Legal Proceedings

The company is involved in a lawsuit against Ascletis Bioscience Co., Ltd., Gannex Pharma Co., Ltd., Ascletis Pharmaceuticals Co., Ltd., Ascletis Pharma Inc., and Jinzi Jason Wu, alleging violation of the Defend Trade Secrets Act, violation of the California Uniform Trade Secrets Act, breach of contract, breach of the implied covenant of good faith and fair dealing, and tortious interference with contract.
The company also filed suit against the same Ascletis Defendants in the International Trade Commission for unlawful and unfair methods of competition.

Related Party Transactions

The company has a Master License Agreement with Ligand Pharmaceuticals Incorporated, granting exclusive worldwide rights to certain clinical and preclinical programs.

Stakeholder Impact

Shareholders: The company's financial performance and clinical progress directly impact shareholder value.
Employees: The company's ability to attract and retain skilled personnel is crucial for its success.
Patients: The company's drug development efforts aim to provide novel therapies for metabolic and endocrine disorders.
Collaborators: The company may seek collaboration arrangements with biopharmaceutical companies for the development or commercialization of its drug candidates.

Next Steps

Report data from the Phase 2 VENTURE study in the first half of 2024.
Obtain results from the biopsy after 52 weeks of dosing in the VOYAGE study in 2024.
Continue clinical trials and preclinical studies for VK2809, VK2735, VK0214, and other programs.
Pursue partnering or licensing opportunities for VK5211.
Seek regulatory approvals for drug candidates.
Commercialize drug candidates if approved.
Raise additional capital to fund operations.

Key Dates

Date	Description
2012-09-24	Viking Therapeutics, Inc. was incorporated in Delaware.
2014-05-21	Entered into a Master License Agreement with Ligand Pharmaceuticals Incorporated.
2015-04-28	Common stock began trading on the Nasdaq Capital Market.
2016-12-01	Received orphan drug designation from the FDA for VK0214 for the treatment X-ALD.
2017-11-01	Announced positive top-line results from a Phase 2 clinical trial for VK5211 in patients who recently suffered a hip fracture.
2019-11-01	Initiated the VOYAGE study, a Phase 2b clinical trial of VK2809 in patients with biopsy-confirmed NASH.
2021-06-01	Initiated a Phase 1b clinical trial of VK0214 in patients with X-ALD.
2022-01-01	Announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735.
2023-01-01	Announced completion of patient enrollment in the VOYAGE study.
2023-03-28	Announced the completion of the Phase 1 trial of VK2735.
2023-03-28	Announced the initiation of a Phase 1 clinical study to evaluate a novel oral formulation of VK2735.
2023-04-03	Completed an underwritten public offering of its common stock.
2023-05-01	Reported that the VOYAGE study successfully achieved its primary endpoint.
2023-07-26	Filed an automatic universal shelf registration statement on Form S-3.
2023-09-01	Initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity.
2023-10-01	Announced completion of patient enrollment in the Phase 2 VENTURE study.
2024-01-01	The company is no longer a smaller reporting company.
2024-06-30	Reassess, as of June 30, 2024, whether we will continue to qualify as a large accelerated filer for filings beyond the fiscal year ending December 31, 2024.

Keywords

VK2809, VK2735, VK0214, VK5211, NASH, X-ALD, Obesity, Metabolic Disorders, Clinical Trials, Biopharmaceutical, Therapeutics

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.